← All tickers

Is SLS Worth Buying in 2026?

SELLAS Life Sciences Group, Inc. Common Stock

STOCK PHARMACEUTICAL PREPARATIONS Updated 2026-06-07

Here’s whether SELLAS Life Sciences Group, Inc. Common Stock (SLS) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bullish.

🟢
Bullish

Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+13.12% over 10 days); RSI 57 — healthy momentum range; strong 1-year return of +404.9%; 3-month momentum positive (+38.1%). Currently 13.5% off its 52-week high. Score: +7/7.

Ready to act on this? 📈 Trade on Webull

SLS is in a confirmed uptrend, trading above both its 50-day ($5.92) and 200-day ($3.64) moving averages. An RSI of 57.3 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +404.9% compares to +24.4% for SPY (beat the market by 380.5%).

$10,000 invested 1 year ago → $50,491 today
vs. S&P 500 (SPY) — same period beat market by 380.5%

1-Year Price Chart

Daily candles
MA-50 MA-200 Up Down

Signal Check

✓Above 200-day MA ($3.64)
✓Above 50-day MA ($5.92)
✓RSI(14) neutral zone (30–70) — currently 57.3
✓Positive return (+404.9%)
!Within 10% of period high (−13.5%)
Period Range $8.23
$1.39 $9.51
RSI (14) 57.3
0 · OversoldOverbought · 100

Key Metrics

Price$8.23
Period Return+404.9%
Period High$9.51
Period Low$1.39
Drawdown−13.5%
MA-50$5.92
MA-200$3.64
RSI (14)57.3
Avg Volume (30d)9.3M
vs. SPYbeat by 380.5%
Return Rank#51 of 1245

Trade SLS

📈 Trade on Webull 📊 Trade on moomoo 💹 Interactive Brokers